


The claims defining the invention are as follows:

1. A compound having Formula (I) or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,



wherein

each R^1 and R^3 is independently H, F, Cl, Br, CN, NO_2 , $-\text{C}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{OR}^b$, $-\text{C}(=\text{O})\text{NR}^c\text{R}^d$, OR^b , $-\text{NR}^c\text{R}^d$, $\text{R}^b\text{O}-\text{C}_{1-4}$ alkylene, $\text{R}^d\text{R}^c\text{N}-\text{C}_{1-4}$ alkylene, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-4} alkylene, 3- to 12-membered heterocyclyl, (3- to 12-membered heterocyclyl)- C_{1-4} alkylene, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} alkylene, 5- to 10-membered heteroaryl or (5- to 10-membered heteroaryl)- C_{1-4} alkylene, and wherein each of the C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-4} alkylene, 3- to 12-membered heterocyclyl, (3- to 12-membered heterocyclyl)- C_{1-4} alkylene, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} alkylene, 5- to 10-membered heteroaryl and (5- to 10-membered heteroaryl)- C_{1-4} alkylene is independently unsubstituted or substituted with one, two, three or four substituents independently selected from F, Cl, Br, CN, OR^b , $-\text{NR}^c\text{R}^d$, C_{1-6} alkyl, C_{1-6} haloalkyl, $\text{R}^b\text{O}-\text{C}_{1-4}$ alkylene or $\text{R}^d\text{R}^c\text{N}-\text{C}_{1-4}$ alkylene;

n is 0, 1, 2 or 3;


each R^2 is independently F, C_{2-6} alkynyl, OR^b , C_{3-12} carbocyclyl, C_{3-12} carbocyclyl- C_{1-4} alkylene, 3- to 12-membered heterocyclyl, (3- to 12-membered heterocyclyl)- C_{1-4} alkylene, C_{6-10} aryl, C_{6-10} aryl- C_{1-4} alkylene, 5- to 14-membered heteroaryl, (5- to 14-membered heteroaryl)- C_{1-4} alkylene; or two adjacent R^2 , together with the atoms to which they are attached, form a C_{3-12} carbocyclic ring, 3- to 12-membered heterocyclic ring, C_{6-10} aromatic ring or 5- to 10-membered heteroaromatic ring, and wherein each of the C_{2-6} alkynyl, C_{3-12} carbocyclyl, C_{3-12}

carbocyclyl-C₁₋₄ alkylene, 3- to 12-membered heterocyclyl, (3- to 12-membered heterocyclyl)-C₁₋₄ alkylene, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄ alkylene, 5- to 14-membered heteroaryl, (5- to 14-membered heteroaryl)-C₁₋₄ alkylene, C₃₋₁₂ carbocyclic ring, 3- to 12-membered heterocyclic ring, C₆₋₁₀ aromatic ring and 5- to 10-membered heteroaromatic ring is independently unsubstituted or substituted with one, two, three, four or five R', with the proviso that when m is 1, R² is not F;

each R' is independently F, Cl, Br, CN, NO₂, =O, OR^b, -NR^cR^d, R^bO-C₁₋₄ alkylene, R^dR^cN-C₁₋₄ alkylene, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkylene, 3- to 6-membered heterocyclyl, (3- to 6-membered heterocyclyl)-C₁₋₄ alkylene, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄ alkylene, 5- to 6-membered heteroaryl or (5- to 6-membered heteroaryl)-C₁₋₄ alkylene, and wherein each of the C₁₋₁₀ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkylene, 3- to 6-membered heterocyclyl, (3- to 6-membered heterocyclyl)-C₁₋₄ alkylene, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄ alkylene, 5- to 6-membered heteroaryl and (5- to 6-membered heteroaryl)-C₁₋₄ alkylene is independently unsubstituted or substituted with one, two, three, or four substituents independently selected from F, Cl, Br, CN, NO₂, OR^b, -NR^cR^d, C₁₋₆ alkyl, C₁₋₆ haloalkyl, R^bO-C₁₋₄ alkylene or R^dR^cN-C₁₋₄ alkylene;

m is 1 or 2;

X has one of the following sub-formulae:



V' is independently a C₃₋₈ cycloalkane ring, 3- to 8-membered heterocyclic ring, benzene ring or 5- to 6-membered heteroaromatic ring;

each R^w is independently F, Cl, Br, CN, NO₂, =O, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d,

-S(=O)₂R^e, -S(=O)₂NR^cC(=O)R^a, -S(=O)₂NR^cR^d, (R^bO)₂P(=O)-C₀₋₂ alkylene, OR^b, -NR^cR^d, R^bO-C₁₋₂ alkylene, R^dR^cN-C₁₋₂ alkylene, methyl, ethyl, *i*-propyl, *n*-propyl, *n*-butyl, *t*-butyl, tetrazolyl, isoxazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl or pyrazolyl, and wherein each of methyl, ethyl, *i*-propyl, *n*-propyl, *n*-butyl, *t*-butyl, tetrazolyl, isoxazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and pyrazolyl is independently unsubstituted or substituted with one, two, three, or four U; and


each U is independently F, Cl, Br, CF₃, NO₂, CN, =O, N₃, OR^b, -NR^cR^d, methyl, ethyl, *i*-propyl, *n*-propyl, *n*-butyl or *t*-butyl;

each s is independently 0, 1, 2 or 3;

and

each R^a, R^b, R^c, R^d and R^e is independently H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkylene, 3- to 6-membered heterocyclyl, (3- to 6-membered heterocyclyl)-C₁₋₄ alkylene, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄ alkylene, 5- to 10-membered heteroaryl, (5- to 10-membered heteroaryl)-C₁₋₄ alkylene; or R^c and R^d, together with the nitrogen atom to which they are attached, form a 3- to 6-membered heterocyclic ring, and wherein each of the C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkylene, 3- to 6-membered heterocyclyl, (3- to 6-membered heterocyclyl)-C₁₋₄ alkylene, C₆₋₁₀ aryl, C₆₋₁₀ aryl-C₁₋₄ alkylene, 5- to 10-membered heteroaryl, (5- to 10-membered heteroaryl)-C₁₋₄ alkylene and 3- to 6-membered heterocyclic ring is independently unsubstituted or substituted with one, two, three, or four substituents independently selected from F, Cl, CN, OH, NH₂, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy or C₁₋₆ alkylamino.

2. The compound of claim 1 having Formula (II), or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,



wherein A is a C₃₋₁₂ carbocyclic ring, 3- to 12-membered heterocyclic ring, C₆₋₁₀ aromatic ring or 5- to 10-membered heteroaromatic ring; and

q is 0, 1, 2, 3, 4 or 5.

3. The compound of claim 1 or 2, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each R¹ and R³ is independently H, F, Cl, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, OR^b, -NR^cR^d, C₁₋₃ alkyl, C₃₋₆ cycloalkyl, 5- to 6-membered heterocyclyl, phenyl or 5- to 6-membered heteroaryl, and wherein each of the C₁₋₃ alkyl, C₃₋₆ cycloalkyl, 5- to 6-membered heterocyclyl, phenyl or 5- to 6-membered heteroaryl is independently unsubstituted or substituted with one, two, three or four substituents independently selected from F, Cl, OR^b, -NR^cR^d, C₁₋₃ alkyl, C₁₋₃ haloalkyl or R^bO-C₁₋₂ alkylene.

4. The compound of claim 1, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each R² is independently F, C₂₋₆ alkynyl, OR^b, C₃₋₆ carbocyclyl, C₃₋₆ carbocyclyl-C₁₋₂ alkylene, 5- to 6-membered heterocyclyl, (5- to 6-membered heterocyclyl)-C₁₋₂ alkylene, phenyl, naphthyl, phenyl-C₁₋₂ alkylene, 5- to 6-membered heteroaryl, (5- to 6-membered heteroaryl)-C₁₋₂ alkylene; or two adjacent R², together with the atoms to which they are attached, form a C₅₋₆ carbocyclic ring, 5- to 6-membered heterocyclic ring, benzene ring or 5- to 6-membered heteroaromatic ring, and wherein each of the C₂₋₆ alkynyl, C₃₋₆ carbocyclyl, C₃₋₆ carbocyclyl-C₁₋₂ alkylene, 5- to 6-membered heterocyclyl, (5- to 6-membered heterocyclyl)-C₁₋₂ alkylene, phenyl, naphthyl, phenyl-C₁₋₂ alkylene, 5- to 6-membered heteroaryl, (5- to 6-membered heteroaryl)-C₁₋₂ alkylene, C₅₋₆ carbocyclic ring, 5- to 6-membered heterocyclic ring, benzene ring and 5- to 6-membered

heteroaromatic ring is independently unsubstituted or substituted with one, two, three, four or five R', with the proviso that when m is 1, R² is not F.



5. The compound of claim 1 or 2, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each R' is independently F, Cl, Br, CN, NO₂, OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)NR^cR^d, C₁₋₉ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, 5- to 6-membered heterocyclyl, phenyl, phenyl-C₁₋₂ alkylene or 5- to 6-membered heteroaryl, and wherein each of the C₁₋₉ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, 5- to 6-membered heterocyclyl, phenyl, phenyl-C₁₋₂ alkylene and 5- to 6-membered heteroaryl is independently unsubstituted or substituted with one, two, three, or four substituents independently selected from F, Cl, Br, CN, NO₂, OR^b, -NR^cR^d, methyl, ethyl, *n*-propyl or *i*-propyl.



6. The compound of claim 1 or 2, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each R^a, R^b, R^c, R^d and R^e is independently H, methyl, ethyl, *i*-propyl, *n*-propyl, *n*-butyl, *t*-butyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₂ alkylene, 3- to 6-membered heterocyclyl, phenyl, phenyl-C₁₋₂ alkylene; or R^c and R^d, together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic ring, and wherein each of methyl, ethyl, *i*-propyl, *n*-propyl, *n*-butyl, *t*-butyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₂ alkylene, 3- to 6-membered heterocyclyl, phenyl, phenyl-C₁₋₂ alkylene and 5- to 6-membered heterocyclic ring is independently unsubstituted or substituted with one, two, three, or four substituents independently selected from F, Cl, CN, OH, NH₂, C₁₋₃ alkyl, C₁₋₃ haloalkyl or methoxy.

7. The compound of claim 2, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein A is a C₅₋₆ carbocyclic ring, 5- to 6-membered heterocyclic ring, benzene ring, naphthalene ring or 5- to 6-membered heteroaromatic ring.

8. The compound of claim 1, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each R² is independently F, ethynyl, propynyl, OR^b, C₃₋₆ carbocyclyl, 5- to 6-membered heterocyclyl, phenyl, naphthyl, phenyl-C₁₋₂ alkylene, furyl, benzofuryl, pyrrolyl, pyridyl, pyrazolyl, imidazolyl,


benzimidazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, 1,3,5-triazinyl, thiazolyl, thienyl, benzothienyl, pyrazinyl, pyridazinyl, pyrimidyl, indolyl, purinyl, quinolyl, isoquinolyl,

phenoxthynyl,  or , and wherein each ethynyl, propynyl, C₃₋₆ carbocyclyl, 5- to 6-membered heterocyclyl, phenyl, naphthyl, phenyl-C₁₋₂ alkylene, furyl, benzofuryl, pyrrolyl, pyridyl, pyrazolyl, imidazolyl, benzimidazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, 1,3,5-triazinyl, thiazolyl, thienyl, benzothienyl, pyrazinyl, pyridazinyl, pyrimidyl, indolyl, purinyl, quinolyl, isoquinolyl, phenoxthynyl,


 and  is independently unsubstituted or substituted with one, two, three, four or five R', with the proviso that when m is 1, R² is not F.

9. The compound of claim 2, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein A is a C₅₋₆ carbocyclic ring, 5- to 6-membered heterocyclic ring, benzene, naphthalene, furan, benzofuran, pyrrole, pyridine, pyrazole, imidazole, benzoimidazole, triazole, tetrazole, oxazole, oxadiazole, 1,3,5-triazine, thiazole, thiophene, benzothiophene, pyrazine, pyridazine, pyrimidine, indole, purine, quinoline or isoquinoline.




10. The compound of claim 1 having Formula (III), (IV), (V), (VI), (VII) or (VIII), or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,




(III),





(IV),





11. The compound of claim 1 having one of the following structures:





































,




,




,




,




,




,




,




,




,




,




,




,




,




,




,





















,




,



,





or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof.

12. A pharmaceutical composition comprising an effective amount of the compound of any one of claims 1 to 11, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, optionally,

further comprising a pharmaceutically acceptable carrier, adjuvant, vehicle or a combination thereof.

13. The pharmaceutical composition of claim 12 further comprising one or more therapeutic agents, and wherein the therapeutic agent is an anti-influenza virus agent or anti-influenza virus vaccine.

14. The pharmaceutical composition of claim 13, wherein the therapeutic agent is amantadine, rimantadine, oseltamivir, zanamivir, peramivir, laninamivir, laninamivir octanoate hydrate, favipiravir, arbidol, ribavirin, stachyflin, ingavirin, fludase, CAS no.1422050-75-6, JNJ-872, AL-794, an influenza vaccine or a combination thereof.

15. Use of the compound of any one of claims 1 to 11, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, or the

pharmaceutical composition of any one of claims 12 to 14 in the manufacture of a medicament for preventing, managing, treating or lessening a disorder or disease caused by virus infection in a patient,

wherein the virus infection is influenza virus infection.

16. Use of the compound of any one of claims 1 to 11, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, or the pharmaceutical composition of any one of claims 12 to 14 in the manufacture of a medicament for inhibiting RNA polymerase of influenza virus.

17. The compound of any one of claims 1 to 11, or a stereoisomer, a tautomer, an *N*-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, or the pharmaceutical composition of any one of claims 12 to 14 for use in preventing, managing, treating or lessening a disorder or disease caused by virus infection.